Sun Acquisitions

AUGUST 5, 2024

Technology enables more efficient due diligence, valuation, and integration, helping companies identify opportunities and mitigate risks more effectively. Investors are also placing greater emphasis on ESG performance as a critical determinant of company valuations and investment decisions.

M&A 59

M&A Mergers and Acquisitions IPO Valuation 59

Cooley M&A

JANUARY 30, 2024

As we look ahead to the 2024 proxy season (and beyond), let’s review the key 2023 trends and developments from activism playbooks, with a sharp focus on the ever-changing landscape in the technology and healthcare sectors. 10] So, what does place tech and healthcare companies in activist crosshairs? Momentum building for 2024?

Private Equity 52

Private Equity M&A Capital Investors 52

Cooley M&A

JANUARY 23, 2024

Valuation disconnects persist In the post-COVID era, the life sciences market has experienced an increased polarization of successful and distressed companies, with sharp contrasts in liquidity and investment interest as buyers focus on de-risked assets. The results Add all those things together and what do we get? billion.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. Of course, we continue to see many parties discussing licensing deals deciding to do just that – turning to a full acquisition after initial licensing discussions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 25, 2023

However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined private equity sponsor buyers. trillion. [2]

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

MergersCorp M&A International

MAY 27, 2025

The Basics At its core, a SPAC is a shell company with no commercial operations, formed solely to raise capital through an Initial Public Offering (IPO) with the express purpose of acquiring an existing private company. What is a SPAC? The capital is already raised, reducing market uncertainty.

IPO 52

IPO Mergers and Acquisitions Investors Capital 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. billion acquisition of Catalent, a leader in contract manufacturing for cell and gene therapies, stands out as the largest healthcare deal of 2024.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64